Corcept Therapeutics

SOX Manager

Redwood City, California, United States

Auto‑apply with AI Apply

Not SpecifiedCompensation

Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Financial Services, HealthcareIndustries

Requirements

Candidates should possess a Bachelor’s degree in accounting or finance, with a Certified Public Accountant (CPA) designation being a plus, and a minimum of eight years of experience in financial operations. They should have an in-depth understanding of business processes and financial transaction flows, along with experience utilizing accounting software such as NetSuite or Coupa.

Responsibilities

The SOX Manager will assist with the annual SOX planning, scoping, risk assessment, walk-throughs, testing, and reporting for financial processes and in-scope IT applications, serving as a SOX internal control framework advisor to various departments. They will maintain SOX documentation, including process narratives and risk control matrix, manage SOX re-design and testing for new system implementations, perform segregation of duties analysis and fraud risk assessments, and provide assistance to internal and external auditors during the SOX audit process. Additionally, the role involves reviewing key control activities during monthly close and evaluating third-party vendors’ SOC-1 reports.

Skills

SOX

Sarbanes-Oxley

Risk Assessment

Process Reviews

Internal Controls

ERP

Segregation of Duties

Fraud Risk Assessment

Auditing

User Access Review

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Key Metrics

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free